These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 22011982

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial.
    Scirica BM, Bohula EA, Dwyer JP, Qamar A, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Murphy SA, Im K, Leiter LA, Gupta M, Patel T, Miao W, Perdomo C, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD, CAMELLIA-TIMI 61 Steering Committee and Investigators.
    Circulation; 2019 Jan 15; 139(3):366-375. PubMed ID: 30586726
    [Abstract] [Full Text] [Related]

  • 23. Multicenter, placebo-controlled trial of lorcaserin for weight management.
    Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays H, Shanahan WR, Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group.
    N Engl J Med; 2010 Jul 15; 363(3):245-56. PubMed ID: 20647200
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Discovery and development of 5-HT(₂C) receptor agonists for obesity: is there light at the end of the tunnel?
    Miller KJ, Wacker DA.
    Future Med Chem; 2010 Dec 15; 2(12):1761-75. PubMed ID: 21428799
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. 5-HT(2C) receptor agonists and the control of appetite.
    Halford JC, Harrold JA.
    Handb Exp Pharmacol; 2012 Dec 15; (209):349-56. PubMed ID: 22249823
    [Abstract] [Full Text] [Related]

  • 29. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women.
    Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR, APD356-004 Study Group.
    Obesity (Silver Spring); 2009 Mar 15; 17(3):494-503. PubMed ID: 19057523
    [Abstract] [Full Text] [Related]

  • 30. Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease.
    Bays HE.
    Expert Rev Cardiovasc Ther; 2009 Nov 15; 7(11):1429-45. PubMed ID: 19900026
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Drug management of obesity--efficacy versus safety.
    Astrup A.
    N Engl J Med; 2010 Jul 15; 363(3):288-90. PubMed ID: 20647205
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists.
    Higgins GA, Sellers EM, Fletcher PJ.
    Trends Pharmacol Sci; 2013 Oct 15; 34(10):560-70. PubMed ID: 24041919
    [Abstract] [Full Text] [Related]

  • 39. Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia.
    Nesto R, Fain R, Li Y, Shanahan W.
    Postgrad Med; 2016 May 15; 128(4):364-70. PubMed ID: 27116910
    [Abstract] [Full Text] [Related]

  • 40. Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six-month, randomized, placebo-controlled, double-blind clinical trial.
    Tuccinardi D, Farr OM, Upadhyay J, Oussaada SM, Mathew H, Paschou SA, Perakakis N, Koniaris A, Kelesidis T, Mantzoros CS.
    Diabetes Obes Metab; 2019 Jun 15; 21(6):1487-1492. PubMed ID: 30724455
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.